A biotechnology startup in southwestern Japan said Tuesday it will start human clinical trials for a drug to treat COVID-19 in 2021.Bonac Corp., based in Kurume, Fukuoka Prefecture, said it has developed 72 candidates for nucleic acid medicines and tested their effectiveness against the respiratory disease caused by the novel coronavirus, in joint research with the Fukuoka Institute of Health and Environmental Sciences since June.Ten of the candidates had proven to be effective in "significantly reducing the replication" of the virus, demonstrating the effectiveness of these medicines for C…READ FULL ARTICLE